Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic (synchronous or metachronous) or locally advanced, non-resectable, well-differentiated duodeno-pancreatic neuroendocrine tumour, of grade 1 or 2 (WHO 2010 classification; Ki-67 ≤ 20%)~* Progressive before first-line treatment~* Histologically confirmed (either on primary tumour or metastases)~* Pathological diagnosis validated by the NET consulting pathologist~* Documented stable disease or objective response after first-line treatment, within 4 weeks (28 days) prior to randomisation~* The first-line treatment will consist of either a chemotherapy or biotherapy (everolimus or sunitinib) as referred to TNCD or ENETS guidelines. Treatment must have been administered for 3 to 6 months for chemotherapy and for 6 months for biotherapy~* Non-functional tumour or gastrinoma controlled by PPIs~* Age \> or = 18 years~* WHO 0, 1 or 2~* Effective contraception for male or female patients of childbearing age, defined as: oral contraceptives, intra-uterine devices, barrier contraceptive methods along with a spermicide gel, or surgical sterilisation. Female patients should use this contraception throughout the treatment period and for 6 months after the last treatment administration. Male patients should use contraception throughout the treatment period and for 3 months after the last treatment administration.~* Signed informed consent prior to initiation of any study-specific procedures or treatment.~Exclusion Criteria:~* History of haematological malignancy or other cancer, except those treated for more than 5 years and considered as cured, carcinoma in situ of the cervix and treated skin cancer (excluding melanoma)~* Poorly differentiated neuroendocrine carcinoma or NET grade 3 ENETS (Ki-67 \> 20%)~* If primary resected, bone metastasis exclusively~* Pre-treatment by somatostatin long-acting analogue~* Total bilirubin ≥ 60 µmol/L~* Uncontrolled diabetes~* Contraindication to product used in the study or its components~* Tumour arising in the context of a genetic disease~* Pregnancy or lactation~* Patients unable to undergo medical follow-up due to geographical, social, psychological or legal reasons~* Concomitant participation in another clinical trial investigating a treatment during the treatment phase and within 30 days prior to the start of the study treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lanreotide (Type: EXPERIMENTAL): In this arm, patients will receive lanreotide 120 mg every 28 days until disease progression
- placebo (Type: PLACEBO_COMPARATOR): In this arm, patients will receive placebo every 28 days until disease progression

Based on this trial design, predict the completion outcome and termination type (if applicable).